Drug intelligence / Profile preview

ILB-31X

Development stage: Preclinical
Lead developer: ILIAS Biologics
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Unknown (preclinical Stage; Likely Intravenous Or Similar Systemic Route Based On Exosome Therapies)

Overview

ILB-31X is an exosome-based therapeutic candidate developed by ILIAS Biologics. It is designed for the treatment of digestive system disorders, with a primary focus on liver diseases such as alcoholic fatty liver and acute liver failure. The drug utilizes exosomes to deliver a super-repressor form of IκBα (srIκB), which modulates NF-κB activity in Kupffer cells (KCs) within the liver. By inhibiting NF-κB signaling, ILB-31X aims to reduce inflammation and tissue damage associated with alcohol-induced and other forms of liver injury. As of April 2025, its highest development status is preclinical[1][10].

Targets

NF-κB

Beyond the preview

Go deeper on ILB-31X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ILB-31X.

Explore the full profile